Pharmacological and clinical profile of recently approved second-generation antipsychotics: Implications for treatment of schizophrenia in older patients

Jeffrey Rado*, Philip G. Janicak

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Antipsychotics are frequently used in elderly patients to treat a variety of conditions, including schizophrenia. While extensively studied for their impact in younger populations, there is comparatively limited evidence about the effectiveness of these agents in older patients. Further complicating this situation are the high comorbidity rates (both psychiatric and medical) in the elderly; age-related changes in pharmacokinetics that lead to a heightened proclivity for adverse effects; and the potential for multiple, clinically relevant drug interactions. With this background in mind, we review diagnostic and treatment-related issues specific to elderly patients suffering from schizophrenia. We then focus on the potential role of the most recently approved second-generation antipsychotics, paliperidone (both the extended-release oral formulation and the long-acting injectable formulation), iloperidone, asenapine and lurasidone, given the limited clinical experience with these agents in the elderly. While there is limited data to support their safety, tolerability and efficacy in older patients with schizophrenia, each has unique characteristics that should be considered when used in this population.

Original languageEnglish (US)
Pages (from-to)783-791
Number of pages9
JournalDrugs and Aging
Volume29
Issue number10
DOIs
StatePublished - Oct 1 2012

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Pharmacological and clinical profile of recently approved second-generation antipsychotics: Implications for treatment of schizophrenia in older patients'. Together they form a unique fingerprint.

Cite this